Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Utidelone in HER2-negative Advanced or Metastatic Breast Cancer
NCT05403333Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of utidelone in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05403333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403333.